This appointment strengthens NTx’s strategic leadership as company advances next-generation RNA-based therapeutics
RIO RANCHO, N.M. – September 30, 2025 – NTx, a life sciences company developing next-generation platforms for RNA and protein manufacturing, today announced the appointment of Dave Johnson, a globally recognized corporate strategist with deep expertise in mergers, acquisitions, and corporate development, to its Board of Directors.
“Dave brings unmatched experience in strategic growth and corporate leadership,” said Dr. Jamie Coffin, President and CEO of NTx. “His track record of guiding companies through transformational growth will be invaluable as NTx scales its technologies and advances its mission of bringing RNA-based medicines to patients.”
Dave Johnson is a seasoned leader in M&A and corporate strategy, with more than 120 acquisitions representing over $40 billion in equity investment, divestitures, and venture capital transactions. He co-founded TLG Capital Partners and previously served as Senior Managing Director at The Blackstone Group, where he led technology sector investments across cybersecurity, cloud solutions, and IT services.
Earlier in his career, Johnson was the Senior Vice President of Strategy at Dell, where he drove major acquisitions including SecureWorks and Boomi, and held senior leadership roles at IBM. He has also served on numerous corporate boards and holds a B.A. and MBA from Boston College, as well as a PMD from Harvard University.
“I am honored to join the NTx Board of Directors at such an exciting time for the company,” said Dave Johnson. “NTx is at the forefront of advancing RNA-based therapeutics, and I look forward to working with the team to help guide the company’s growth and strategic direction as it brings these transformative therapies to patients.”
About NTx
NTx, based in Rio Rancho, New Mexico, is revolutionizing biomanufacturing with cutting-edge solutions tailored to the demands of modern research and personalized medicine. NTx is developing innovative systems like NTxscribe® and NTxpress® to enable the sustainable production of mRNA and protein therapeutics, offering scalability from personalized doses to mass-market volumes. Discover how NTx is enabling the future of medicine at www.ntxbio.com.
Media Contact
Kalyn Schieffer for NTx - kos@anzupartners.com